PharmiWeb.com - Global Pharma News & Resources
10-May-2021

How the Aortic Valve Market Has Witnessed Substantial Growth in Coming Years?

The global aortic valve market is predicted to attain a revenue of $29,146.9 million by 2030, advancing at a 13.2% CAGR during the forecast period (2020–2030), according to a report by P&S Intelligence. A key factor leading to the growth of the market is the increasing prevalence of aortic regurgitation and aortic stenosis. Rheumatic heart disease (RHD) is the most common cause of aortic regurgitation.

Request to view sample of this market research: https://www.psmarketresearch.com/market-analysis/aortic-valve-market/report-sample

As per the World Health Organization, about 2% of the population suffering from cardiovascular diseases are also affected by RHD, i.e. approximately 33 million people all over the globe are suffering from RHD. This increasing prevalence of RHD is expected to result in the growth of the aortic valve domain in the years to come. At the present time, however, the market is being severely affected because of the COVID-19 pandemic, as health services are under immense pressure.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=aortic-valve-market

When procedure is taken into consideration, the aortic valve market is divided into open surgery and minimally invasive surgery (MIS), between which, the MIS division held the major value share of the market in 2019. The division is further predicted to register the higher CAGR in the years to come. Minimally invasive aortic valve replacement is primarily done by utilizing the transfemoral approach that is allowed by the large diameter of the artery, thereby letting the catheter pass easily through it.

On the basis of suture type, the aortic valve market is categorized into sutureless and sutured, between which, the sutureless division is expected to advance at a faster pace in the near future. As the use of sutures is eliminated during the replacement of aortic valves, the procedure leads to a cardiopulmonary bypass duration and cross-clamping. The further facilitates complex cardiac interventions and a minimally invasive process, all the while maintaining low paravalvular leak rates and satisfactory hemodynamic outcomes.   

 

Editor Details

Related Links

Last Updated: 11-May-2021